CY1115665T1 - Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv - Google Patents

Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv

Info

Publication number
CY1115665T1
CY1115665T1 CY20141100755T CY141100755T CY1115665T1 CY 1115665 T1 CY1115665 T1 CY 1115665T1 CY 20141100755 T CY20141100755 T CY 20141100755T CY 141100755 T CY141100755 T CY 141100755T CY 1115665 T1 CY1115665 T1 CY 1115665T1
Authority
CY
Cyprus
Prior art keywords
forms
inspector
psychological
hiv protection
hiv
Prior art date
Application number
CY20141100755T
Other languages
English (en)
Inventor
Hans Wim Pieter Vermeersch
Daniel Joseph Christiaan Thoné
Luc Donné Marie-Louise Janssens
Piet Tom Bert Paul Wigernick
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115665(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Publication of CY1115665T1 publication Critical patent/CY1115665T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αποκαλύπτονται νέες ψευδοπολυμορφικές μορφές του (3R,3aS,6aR)-εξαϋδροφουρο[2,3-b] φουραν-3-υλ (1S,2R)-3-[[4-αμινοφαινυλ) σουλφονυλ] (ισοβουτυλ) αμινο]-1-βενζυλ-2-υδροξυπροπυλκαρβαμιδικού και διαδικασίες για την παραγωγή τους.
CY20141100755T 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv CY1115665T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
EP10180831.9A EP2314591B2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (1)

Publication Number Publication Date
CY1115665T1 true CY1115665T1 (el) 2017-01-25

Family

ID=29724454

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100755T CY1115665T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20141100756T CY1117928T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20171100896T CY1119311T1 (el) 2002-05-16 2017-08-23 Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20141100756T CY1117928T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20171100896T CY1119311T1 (el) 2002-05-16 2017-08-23 Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv

Country Status (26)

Country Link
US (8) US7700645B2 (el)
EP (4) EP1567529B2 (el)
JP (1) JP4864320B2 (el)
KR (2) KR20100119906A (el)
CN (1) CN100475819C (el)
AP (1) AP2052A (el)
AU (2) AU2003271740B2 (el)
BR (1) BRPI0311176B8 (el)
CA (1) CA2485834C (el)
CY (3) CY1115665T1 (el)
DK (3) DK2767539T3 (el)
EA (1) EA007120B8 (el)
ES (4) ES2498370T5 (el)
HK (1) HK1081969A1 (el)
HR (1) HRP20041061B1 (el)
HU (1) HUE034389T2 (el)
IL (1) IL165140A0 (el)
LT (1) LT2767539T (el)
MX (1) MXPA04011427A (el)
NO (1) NO331477B1 (el)
NZ (1) NZ536497A (el)
PL (1) PL215151B1 (el)
PT (3) PT2767539T (el)
SI (3) SI2314591T2 (el)
WO (1) WO2003106461A2 (el)
ZA (1) ZA200410154B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336160C (en) 1998-06-23 2015-02-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of compounds for treating hiv
AU2003271740B2 (en) 2002-05-16 2010-05-13 Janssen R&D Ireland Pseudopolymorphic forms of a HIV protease inhibitor
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
RS51073B (sr) 2003-12-23 2010-10-31 Tibotec Pharmaceuticals Ltd. Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata
MX2007010378A (es) 2005-02-25 2007-09-25 Tibotec Pharm Ltd Sintesis del precursor inhibidor de la proteasa.
PL2089371T3 (pl) * 2006-11-09 2011-06-30 Janssen Sciences Ireland Uc Sposoby wytwarzania heksahydrofuro[2,3-b]furan-3-olu
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
PL2381786T3 (pl) 2009-01-29 2015-06-30 Mapi Pharma Ltd Dimetylosulfotlenkowy solwat darunawiru
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
WO2011048604A2 (en) * 2009-09-17 2011-04-28 Matrix Laboratories Limited An improved process for the preparation of darunavir
BR112012009956A2 (pt) 2009-10-30 2015-09-29 Lupin Ltd um novo processo para a preparação de darunavir e etanolato darunavir de tamanho de partícula.
CN102686594A (zh) * 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物
WO2011083287A2 (en) * 2010-01-05 2011-07-14 Cipla Limited Darunavir polymorph and process for preparation thereof
WO2011092687A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Hk Limited Process for the preparation of darunavir and darunavir intermediates
US8853430B2 (en) * 2010-05-20 2014-10-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
DK2729130T3 (en) 2011-07-07 2017-12-11 Janssen Sciences Ireland Uc Darunavir-COMBINATION FORMULATIONS
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
EP2804869B1 (en) * 2012-01-18 2019-06-12 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
ES2969589T3 (es) * 2012-07-24 2024-05-21 Laurus Labs Ltd Solvato de Propionato de Darunavir
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
AU2016233113B2 (en) 2015-03-19 2020-05-07 Mycovia Pharmaceuticals, Inc. Antifungal compounds and processes for making
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ATE174587T1 (de) 1993-08-24 1999-01-15 Searle & Co Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
PT812320E (pt) * 1995-02-22 2000-12-29 Aventis Pharma Ltd Firetanido amorfo piretanido polimorfo processo para a sua preparacao e sua utilizacao
ZA984514B (en) * 1997-05-29 1998-11-30 Merck & Co Inc Hiv protease inhibitor
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
CA2336160C (en) * 1998-06-23 2015-02-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of compounds for treating hiv
US6225317B1 (en) 1998-11-19 2001-05-01 Dupont Pharmaceuticals Company Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone
SI1159278T1 (sl) 1999-02-12 2006-06-30 Vertex Pharma Inhibitorji aspartil proteaze
AU2003271740B2 (en) 2002-05-16 2010-05-13 Janssen R&D Ireland Pseudopolymorphic forms of a HIV protease inhibitor
WO2011083287A2 (en) * 2010-01-05 2011-07-14 Cipla Limited Darunavir polymorph and process for preparation thereof

Also Published As

Publication number Publication date
HK1081969A1 (en) 2006-05-26
US7700645B2 (en) 2010-04-20
EP2767539B1 (en) 2017-07-12
ZA200410154B (en) 2005-12-28
SI2767539T1 (sl) 2017-10-30
KR101128370B1 (ko) 2012-04-23
EA200401503A1 (ru) 2005-06-30
AP2004003191A0 (en) 2004-12-31
WO2003106461A3 (en) 2004-05-13
PT2767539T (pt) 2017-08-28
SI2314591T1 (sl) 2014-11-28
CY1117928T1 (el) 2017-05-17
CY1119311T1 (el) 2018-02-14
EP2314591A1 (en) 2011-04-27
US10000504B2 (en) 2018-06-19
US20210179631A1 (en) 2021-06-17
AU2012205289A1 (en) 2012-08-09
PL215151B1 (pl) 2013-10-31
BRPI0311176B1 (pt) 2019-08-20
CN100475819C (zh) 2009-04-08
EP1567529A2 (en) 2005-08-31
ES2498370T5 (es) 2021-11-24
NO20045409L (no) 2004-12-10
CA2485834A1 (en) 2003-12-24
US20150336980A1 (en) 2015-11-26
AP2052A (en) 2009-10-05
KR20050008715A (ko) 2005-01-21
DK2767539T3 (en) 2017-09-11
ES2503551T3 (es) 2014-10-07
DK1567529T4 (da) 2021-05-10
NO331477B1 (no) 2012-01-16
EP2314591B2 (en) 2021-02-24
EP3045460B1 (en) 2019-04-17
US20130303790A1 (en) 2013-11-14
BR0311176A (pt) 2005-03-15
US20050250845A1 (en) 2005-11-10
JP4864320B2 (ja) 2012-02-01
ES2728735T3 (es) 2019-10-28
BRPI0311176B8 (pt) 2021-05-25
SI1567529T2 (sl) 2021-08-31
ES2638412T3 (es) 2017-10-20
KR20100119906A (ko) 2010-11-11
NZ536497A (en) 2006-08-31
EP1567529B1 (en) 2014-06-18
JP2005533068A (ja) 2005-11-04
US20170260196A1 (en) 2017-09-14
EP3045460A1 (en) 2016-07-20
DK2314591T3 (da) 2014-09-22
US20180312517A1 (en) 2018-11-01
CA2485834C (en) 2007-07-17
CN1668623A (zh) 2005-09-14
DK1567529T3 (da) 2014-09-15
EP2314591B1 (en) 2014-06-18
EA007120B1 (ru) 2006-06-30
PT1567529E (pt) 2014-09-09
EP2767539A1 (en) 2014-08-20
US10858369B2 (en) 2020-12-08
AU2003271740A1 (en) 2003-12-31
AU2003271740B2 (en) 2010-05-13
LT2767539T (lt) 2017-09-25
DK2314591T4 (da) 2021-05-10
EA007120B8 (ru) 2012-03-30
US20140171499A1 (en) 2014-06-19
EP1567529B2 (en) 2021-02-24
IL165140A0 (en) 2005-12-18
HRP20041061B1 (hr) 2015-02-27
ES2503551T5 (es) 2021-10-28
PL374321A1 (en) 2005-10-17
PT2314591E (pt) 2014-09-19
HUE034389T2 (en) 2018-02-28
WO2003106461A2 (en) 2003-12-24
US20100204316A1 (en) 2010-08-12
ES2498370T3 (es) 2014-09-24
SI1567529T1 (sl) 2014-11-28
US8518987B2 (en) 2013-08-27
SI2314591T2 (sl) 2021-08-31
HRP20041061A2 (en) 2006-07-31
MXPA04011427A (es) 2005-02-17

Similar Documents

Publication Publication Date Title
CY1115665T1 (el) Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
NO20063401L (no) Fremgangsmate for fremstillingen av (3R,3AS,6AR)-heksahydrofuro [2,3-B]furan-3-yl (1S,2R)-3-[[(4-aminofenyl)sulfonyl](isobutyl) amino]-1-benzyl-2-hydroksypropylkarbamat
RS51675B (en) METHODS FOR THE PREPARATION OF HEXAHIDROFURO [2,3-B] FURAN-3-OLA
ZA200609008B (en) Methods for the preparation of (3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-ol
CY1106214T1 (el) Ανθελονοσιακα 1,2,4 - τριοξολανιου
BR0212341A (pt) Processo para a preparação de hexaidro-furo[2,3-b]furan-3-ol
ES2009839B3 (es) Rodamiento de bolas con pretensado y procedimiento y herramienta parasu fabricacion.
EP1652489A3 (en) Measured object mounting tool and production method of three-dimensional shape data of dental prosthesis
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
ATE475883T1 (de) Verfahren zur messung der wirkstärke von glatirameracetat
ECSP045255A (es) Cumarinas utiles como biomarcadores
CY1117133T1 (el) Ανθελονοσιακα δισπειρο-1,2,4-τριοξολανιων
AU2003287038A1 (en) METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS
CY1105856T1 (el) ΠΑΡΑΣΚΕΥΗ ΤΩΝ ΣΤEPΕΟΪΣΟΜEPΩΝ ΤΗΣ (3ΑΛΦΑ, 3ΑΛΦΑ/ΒΗΤΑ, 6ΑΛΦΑ/ΒΗΤΑ) ΕΞΑΫΔΡΟΦΟΥΡΟ [2,3-b] ΦΟΥΡΑΝ-3-ΟΛΗΣ
BRPI0917377A2 (pt) processo para a preparacao de (1s,2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato de (3r,3as,6ar)-hexahidrofuro[2,3-b] furan-3-ila
CY1115148T1 (el) Ανθελονοσιακα δισπειρο 1,2,4-τριοξολανια
ES2172125T3 (es) Procedimiento de fabricacion de un cigueñal.
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
BR0213360A (pt) Processo para a preparação do 14beta-hidróxi-bacatina iii-1,14 -carbonato